Company: VEEV
Filing Date: 2025-05-05
Form Type: DEF 14A
Source: 0001140361-25-017353
Chunk: 23

Company: VEEVA SYSTEMS INC
Filing Date: 2025-05-05
Form: DEF 14A
Chunk 23
---
, values regular input from shareholders and stakeholders. We, therefore, have several means by which we receive and seek that input. These include:

| • | Shareholder participation in our annual meeting, both via voting and via the opportunity to ask questions or make comments; |

| • | Shareholder-director engagement, both initiated by us and by shareholders; |

| • | Shareholder participation in our regular earnings calls and during the many conferences and other events at which we offer shareholder dialogue, including our Investor Day typically held in the fall; |

| • | Use of any of our compliance or hotline reporting functions; |

| • | Participating in any of the director education or similar governance events attended by our directors or executives; and |

| • | Writing to us either to the address of our physical headquarters or using our dedicated investor relations email address. |

Shareholders and other interested parties wishing to communicate in writing with our Board or with an individual member of our Board, including our Chair who presides over Board executive sessions, may do so by mailing to the Board or to the particular member of the Board, care of the Corporate Secretary, a letter to our principal executive offices, Attention: Corporate Secretary, Veeva Systems Inc., 4280 Hacienda Drive, Pleasanton, California 94588. The envelope should indicate that it contains a shareholder or interested party communication. All such communications will be forwarded to the director or directors to whom the communications are addressed.

| 28Veeva Systems Inc. | 2025 Proxy Statement |

TABLE OF CONTENTS

OUR COMPANY Overview Veeva is the leading provider of industry cloud solutions for the global life sciences industry. Our offerings span cloud software, data, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development through commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. For information about our business highlights for fiscal 2025, please see our Earnings Prepared Remarks for the quarters ended April 31, 2024, July 31, 2024, October 31, 2024, and January 31, 2025, all available on the Investors portion of our website at ir.veeva.com, as well as our Current Reports on Form 8-K furnished on May 30, 2024, August 28, 2024, December 5, 2024